An answer to colon cancer treatment by mesenchymal stem cell originated from adipose tissue

Document Type: Original Article


1 Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Istanbul Yeni Yuzyil University, Istanbul, Turkey

2 Department of Molecular Medicine, Aziz Sancar Institute for Experimental Medicine, Istanbul University, Istanbul, Turkey

3 Department of Hematology, Baskent University, Adana, Turkey

4 Faculty of Life and Natural Sciences, Abdullah Gul University, Kayseri, Turkey

5 Department of Molecular Biology and Genetics, Izmir Institute of Technology, Urla, Izmir, Turkey


Objective(s): Colon cancer is risen up with its complex mechanism that directly impacts on its treatment as well as its common prevalence. Mesenchymal stem cells (MSCs) have been considered as a therapeutic candidate for conventional disease including cancer. In this research, we have focused on apoptotic effects of adipose tissue-derived MSCs in colon cancer.
Materials and Methods: MSCs were obtained from adipose tissue and characterized by Flowcytometer using suitable antibodies. MSCs, HT-29, HCT-116, RKO and healthy cell line MRC5 were cultured by different seeding procedure. After cell viability assay, changes in caspase 3 enzyme activity and the level of phosphatidylserine were measured.
Results: For cell viability assay, a 48 hr incubation period was chosen to seed all cells together. There was a 1.36-fold decrease in caspase 3 enzyme activity by co-treatment of RKO and MSCs in addition to 2.02-fold decrease in HT-29 and MSCs co-treatment, and 1.103-fold increase in HCT-116 and MSCs. The results demonstrated that HCT-116 led to the highest rate of apoptotic cell death (7.5%) compared with other cells.
Conclusion: We suggest that MSCs might remain a new treatment option for cancer by its differentiation and repair capacity.


Main Subjects

1. Nakaji S, Umeda T, Shimoyama T, Sugawara K, Tamura K, Fukuda S, et al. Environmental factors affect colon carcinoma and rectal carcinoma in men and women differently. Int J Colorectal Dis 2003; 18: 481–486.
2. Saif MW, Chu E. Biology of colorectal cancer. Cancer J 2010;16:196–201.
3. Koliaraki V, Pallangyo CK, Greten FR, Kollias G. Mesenchymal cells in colon cancer. Gastroenterology 2017; 152:964-979.
4. Niv Y, Goel A, Boland CR. JC virus and colorectal cancer: a possible trigger in the chromosomal instability pathways. Curr Opin Gastroenterol 2005; 21: 85–89.
5. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr. 2001;131:3 109–120.
6. Slattery ML. Diet, lifestyle, and colon cancer. Semin Gastrointest Dis 2000;11:142–146.
7. Mishra J, Drummond J, Quazi SH, Karanki SS, Shaw JJ, Chen B, et al. Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosis. Crit Rev Oncol Hematol 2013; 86: 232–250.
8. Bergfeld SA, DeClerck YA. Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Cancer Metastasis Rev 2010; 29: 249–261.
9. Sunay O, Can G, Cakir Z, Denek Z, Kozanoglu I, Erbil G, et al. Autologous rabbit adipose tissue-derived mesenchymal stromal cells for the treatment of bone injuries with distraction osteogenesis. Cytotherapy 2013; 15: 690-702.
10. Bieback K, Kem S, Kocaomer A, Ferlik K, Bugert P. Comparing mesenchymal stromal cells from different human tissues: bone marrow, adipose tissue and umbilical cord blood. Biomed Mater Eng 2008; 18: 71-76.
11. Kozanoglu I, Boga C, Ozdogu H, Sozer O, Maytalman E, Yazici AC, et al. Human bone marrow mesenchymal cells express NG2: possible increase in discriminative ability of flow cytometry during mesenchymal sstromal cell identification. Chtotherapy 2009;11:527-533.
12. Kalinina NI, Sysoeva VY, Rubina KA, Parfenova YV, Tkachuk VA. Mesenchymal stem cells in tissue growth and repair. Acta Naturae 2011; 3: 30-37.
13. Williams AR, Hare JM. Mesenchymal stem cells: Biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res 2011;109: 923-940.
14. Hong HS, Kim YH, Son Y. Perspectives on mesenchymal stem cells: Tissue repair, immune modulation, and tumor homing. Arch Pharm Res 2012;35:201.
15. Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira II, et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi’s sarcoma. J Exp Med 2006; 203: 1235–1247.
16. Xu WT, Bian ZY, Fan QM, Li G, Tang TT. Human mesenchymal stem cells (hMSCs) target osteosarcoma and promote its growth and pulmonary metastasis Cancer Lett 2009; 281: 32–41.
17. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009; 4:e4992.
18. Zhu W, Xu W, Jiang R, Qian H, Chen M, Hu J, et al. Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol 2006; 80: 267–274.
19. Lanza C, Morando S, Voci A, Canesi L, Principato MC, Serpero LD, et al. Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo. J Neurochem 2009; 110:1674–1684.
20. Hogan NM, Joyce MR, Murphy JM, Barry FP, O’Brien T, Kerin MJ, et al. Impact of Mesenchymal Stem Cell secreted PAI-1 on colon cancer cell migration and proliferation. Biochem Biophys Res Commun 2013; 435: 574–579.
21. Lu YR, Yuan Y, Wang XJ, Wei LL, Chen YN, Cong C, et al. The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo. Cancer Biol Ther 2008; 7: 245–251.